Signature of a 15.0 million financing deal with the European Investment Bank
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
AB Science to present results from its AB07015 study in severe asthma at the annual European Respiratory Society International Congress
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
AB Science to present results from its AB07002 study in progressive forms of MS at MSVirtual2020
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro
02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19
Results of the Combined General Shareholders’ Meeting of August 31, 2020
01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020
New results published in Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
08/07/2020 – AB Science announces that new results published in the peer-reviewed Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
Presentation of the results from AB8939 preclinical program in AML in EHA 2020 Annual Congress
10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress
Postponement of AB Science Annual General Shareholders’ meeting
22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting
Live webcast on masitinib in combination with isoquercetine for the treatment of COVID-19 on Monday May 11, 2020
07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020
Presentation of the results from the Phase 3 AB07015 study in severe asthma at the EAACI 2020 Annual Congress
07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress